Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business UpdateGlobeNewsWire • 11/06/26
Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral SupportGlobeNewsWire • 10/15/26
Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire • 09/08/26
Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued PipelineSeeking Alpha • 08/11/26
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHAGlobeNewsWire • 05/20/26
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations TranscriptSeeking Alpha • 05/20/26
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026GlobeNewsWire • 05/18/26
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBCGlobeNewsWire • 05/15/26
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/13/26
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual MeetingGlobeNewsWire • 04/27/26
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdateGlobeNewsWire • 03/10/26
Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer TranscriptSeeking Alpha • 02/24/26
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder CancerGlobeNewsWire • 02/23/26
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 02/02/26
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers SymposiumGlobeNewsWire • 01/22/26
Protara Therapeutics, Inc. (TARA) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 MilestonesGlobeNewsWire • 01/12/26
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/07/26
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic MalformationsGlobeNewsWire • 01/05/26